Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiakucao Xiaoliu Mixture is a Traditional Chinese Medicine (TCM) hospital preparation developed by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated with the Shanghai University of Traditional Chinese Medicine. Primarily indicated for the treatment of gastric cancer, it is formulated based on the TCM principles of clearing heat, detoxifying, and resolving phlegm to dissipate masses. The mixture's primary active component is derived from *Prunella vulgaris* (Xiakucao). Research suggests its mechanism of action involves the inhibition of the PI3K/Akt signaling pathway and the downregulation of vascular endothelial growth factor (VEGF), which collectively lead to the suppression of tumor cell proliferation, induction of apoptosis, and inhibition of angiogenesis. It is typically used as an adjuvant therapy alongside conventional treatments to improve clinical outcomes and patient quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiakucao xiaoliu mixture.